Sequence: CFRRGGGG-IMI
| Experiment Id | EXP000481 |
|---|---|
| Paper | Smart, tumor-targeted, and responsive intracellular delivery engineering (STRIDE) nanoplatform: co-d |
| Peptide | FRRG-IMI |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | Lipid nanoparticle (LNP), peptide-modified |
| Formulation Components | Ionizable lipid (DLin-MC3-DMA), DSPC, cholesterol, PEG-lipid; DSPE-PEG2000-peptide conjugate (FRRG-IMI or OctaR-FRRG-IMI); payload: siGLI1 (± Pro-DDP) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | A549/DDP xenograft-bearing female BALB/c nude mice |
| Administration Route | Tail vein injection |
| Output Type | In vivo biodistribution / antitumor efficacy (tumor growth curves/weights) |
| Output Value | |
| Output Units | |
| Output Notes | FI-LNPs showed strong tumor fluorescence accumulation (Cy5-siRNA imaging) and contributed to tumor growth inhibition when carrying siGLI1 or Pro-DDP, but in vivo GLI1 knockdown was explicitly confirmed for the RFI-LNP@siGLI1/DDP group (not for FI-LNPs). |
| Toxicity Notes | |
| Curation Notes |